Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.
Saved in:
| Title: | Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. |
|---|---|
| Authors: | Hill JA; Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Menon MP; Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Dhanireddy S; Department of Medicine, University of Washington, Seattle, Washington, USA., Wurfel MM; Department of Medicine, University of Washington, Seattle, Washington, USA., Green M; Department of Medicine, University of Washington, Seattle, Washington, USA., Jain R; Department of Medicine, University of Washington, Seattle, Washington, USA.; University of Washington School of Pharmacy, Seattle, Washington, USA., Chan JD; Department of Medicine, University of Washington, Seattle, Washington, USA.; University of Washington School of Pharmacy, Seattle, Washington, USA., Huang J; Department of Medicine, University of Washington, Seattle, Washington, USA.; University of Washington School of Pharmacy, Seattle, Washington, USA., Bethune D; University of Washington School of Medicine, Seattle, Washington, USA., Turtle C; Department of Medicine, University of Washington, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Johnston C; Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Xie H; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Leisenring WM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Nina Kim H; Department of Medicine, University of Washington, Seattle, Washington, USA., Cheng GS; Department of Medicine, University of Washington, Seattle, Washington, USA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. |
| Source: | Journal of medical virology [J Med Virol] 2021 Apr; Vol. 93 (4), pp. 2270-2280. Date of Electronic Publication: 2020 Nov 22. |
| Publication Type: | Journal Article; Observational Study |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1096-9071 |
|---|---|
| DOI: | 10.1002/jmv.26674 |
